Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study. [electronic resource]
Producer: 20061114Description: iv18-24 p. digitalISSN:- 0923-7534
- Adolescent
- Adult
- Aged
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Combined Modality Therapy
- Deoxycytidine -- administration & dosage
- Disease-Free Survival
- Female
- Hematopoietic Stem Cell Mobilization
- Humans
- Ifosfamide -- administration & dosage
- Lymphoma, B-Cell -- pathology
- Lymphoma, Follicular -- pathology
- Lymphoma, Large B-Cell, Diffuse -- pathology
- Lymphoma, Mantle-Cell -- pathology
- Male
- Middle Aged
- Neoplasm Recurrence, Local -- pathology
- Organoplatinum Compounds -- administration & dosage
- Oxaliplatin
- Pilot Projects
- Remission Induction
- Rituximab
- Salvage Therapy
- Stem Cell Transplantation
- Survival Rate
- Transplantation, Autologous
- Treatment Outcome
- Gemcitabine
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.